What the changes say
- CF medicines still generate substantially all net product revenue, making manufacturing, safety, competition, and reimbursement especially consequential.
- CASGEVY revenue depends on acceptance despite complex, costly manufacturing and side effects from myeloablative conditioning.
- JOURNAVX and pain programs face lower-cost alternatives, launch challenges, and uncertain follow-on development.
- Expanded pipeline and global operations increase clinical, regulatory, supply, intellectual-property, compliance, and talent demands.
What changed since the prior 10-K
New
- NewRisks Related to Our Business and Products
Our success depends on our ability to develop and commercialize additional medicines
Failure to develop and commercialize additional medicines could leave Vertex dependent on existing products and materially harm the business.
- NewRisks Related to Our Business and Products
Our business is substantially dependent on the success of our CF medicines
Because CF medicines generate substantially all product revenue, competition, supply problems, safety issues, or reimbursement failures could materially disrupt Vertex.
- NewRisks Related to Our Business and Products
We may not be able to increase or maintain CASGEVY product revenues
CASGEVY revenue may not grow or persist because cell collection, manufacturing, administration, costs, reimbursement, and myeloablative conditioning are challenging.
- NewRisks Related to Commercialization
We are subject to pricing and reimbursement pressures that could have a material adverse effect on our business, revenues, and results of operations
Government and private payors may impose price controls, restricted access, mandatory substitution, or other measures that reduce product revenue.
- NewRisks Related to Commercialization
In most markets outside of the U.S., the pricing and reimbursement medicines is subject to governmental control and governments are making greater efforts to reduce drug prices and limit drug spending. The reimbursement process in ex-U.S
Outside the U.S., country-specific government pricing and reimbursement decisions may be delayed, reduced, or withdrawn because of budget and political pressures.
- NewRisks Related to Commercialization
Competing products and technological advances from our competitors may negatively affect our business and market position
Competitors with better efficacy, safety, pricing, reimbursement, technology, or resources could reduce demand for Vertex products and candidates.
- NewRisks Related to Product Development
The data from our product development activities may not support advancement or regulatory approval of our product candidates, or label expansions for our marketed products, or provide sufficient data to support the successful commercialization of our approved products
Clinical and non-clinical data may fail to support efficacy, safety, regulatory approval, label expansion, or commercialization, as illustrated by VX-264.
- NewRisks Related to Product Development
If we fail to successfully conduct our clinical activities, our clinical trials or future regulatory approvals may be delayed or denied
Clinical trials may be delayed or fail because of enrollment, retention, safety, regulatory, supply, site, or novel cell and gene therapy challenges.
- NewRegulatory, Intellectual Property and Other Legal Risks
The extensive regulatory framework governing the health care industry could adversely affect our ability to obtain approval and market our medicines and failure to comply with these regulations could result in fines, penalties or other non-monetary remedies
Expanding health-care regulation could delay approvals or require changes to manufacturing, product communications, and safety reporting, with noncompliance penalties.
- NewRegulatory, Intellectual Property and Other Legal Risks
Commercialization of our products requires that we operate in compliance with applicable health care laws, including laws regulating promotional activities, prohibiting fraud and abuse and requiring reporting of government pricing information
Marketing practices and patient-support programs could be viewed as improper promotion or fraud, leading to corrective action, fines, penalties, or criminal enforcement.
- NewRegulatory, Intellectual Property and Other Legal Risks
If we are unable to obtain, maintain and enforce our intellectual property rights, our business could be harmed
Vertex may fail to obtain, maintain, or enforce patents, trademarks, copyrights, trade secrets, or regulatory exclusivity protecting its products and technology.
- NewRegulatory, Intellectual Property and Other Legal Risks
If we are not able to operate without infringing upon intellectual property rights of third parties, our business could be harmed
Third-party intellectual-property claims could force Vertex to pay royalties, redesign products, incur damages, or stop manufacturing or selling affected products.
- NewRegulatory, Intellectual Property and Other Legal Risks
We are subject to a variety of evolving and developing data privacy and security laws and regulations in various jurisdictions related to the collection, storage, use, sharing, and security of personal data, including health information
- NewRisks Related to Our Operations
If we are unable to maintain and expand our supply chain and manufacturing capabilities, our ability to develop our product candidates and manufacture our products would be harmed
- NewRisks Related to Our Operations
Reliance on third-party relationships could adversely affect our business
- NewRisks Related to Our Operations
Our global operations subject us to risks that could adversely affect our business and revenue. In addition to the ex-U.S
- NewRisks Related to Our Operations
If any of the above risks were to occur, our revenues, results of operations, financial condition or business could be materially harmed
- NewRisks Related to Our Operations
A breakdown or breach of our information technology systems, or unauthorized access to confidential information could adversely affect our business
- NewRisks Related to Our Operations
Cyber-attacks and incidents are increasing in their frequency, sophistication, and intensity, and are difficult to detect
- NewRisks Related to Our Operations
Our operations may be disrupted by the occurrence of a natural disaster, catastrophic event, or by other serious accidents occurring at our facilities
- NewStrategic and Financial Risks
Our business development strategy, including strategic transactions and collaborations, may not be successful, and there may be delays or failures in realizing the anticipated benefits of these activities
- NewStrategic and Financial Risks
In addition, future strategic transactions could result in potentially dilutive issuances of equity securities or the incurrence of debt
- NewStrategic and Financial Risks
Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate globally
- NewStrategic and Financial Risks
Changes in foreign currency rates, interest rate risks, the value of our investment portfolio, and inflation affect our results of operations and financial condition
Dropped
- DroppedRisks Related to Our Business
If we are unable to successfully develop and commercialize additional products, our business could be materially harmed
General failure to develop and commercialize therapies across CF, SCD, TDT, pain, IgAN, AMKD, T1D, DM1, and ADPKD.
- DroppedRisks Related to Our Business
If we are unable to sustain and grow revenues from sales of our CF medicines, our business would be materially harmed and the market price of our common stock would likely decline
Dependence on sustaining and growing CF revenue, including next-generation medicines and expanded access for younger children.
- DroppedRisks Related to Our Business
If we are not successful in commercializing CASGEVY, our revenue growth could be limited and our business could be materially harmed
- DroppedRisks Related to Our Business
If our competitors bring products with superior product profiles to market, our products may not be competitive, and our revenues could decline
CASGEVY commercialization risk, including Vertex’s limited experience commercializing cell and genetic therapies.
- DroppedRisks Related to Our Business
If physicians and patients do not accept our products, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would decline in future periods
Competitors developing superior products for CF, SCD, TDT, pain, and other targeted therapeutic areas.
- DroppedRisks Related to Our Business
Cell and genetic therapies face increased scrutiny from the public and medical communities and commercial success will depend, in part, upon the acceptance of those communities
- DroppedRisks Related to Pricing of Our Products
Government and other third-party payors seek to contain costs of health care through legislative and other means
Physician and patient acceptance, treatment persistence, and adherence risks affecting product revenue.
- DroppedRisks Related to Pricing of Our Products
We may experience pricing pressure on our products, which could reduce our revenues and future profitability
Public and medical-community acceptance of cell and genetic therapies, including CASGEVY.
- DroppedRisks Related to Pricing of Our Products
Current health care laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. health care system may affect our ability to commercialize our marketed products profitably
Third-party payors’ failure to provide adequate coverage and reimbursement for Vertex products.
- DroppedRisks Related to Pricing of Our Products
We have experienced challenges commercializing products outside of the U.S., and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products in ex-U.S. markets
State drug-pricing legislation and transparency requirements creating product pricing pressure.
- DroppedRisks Related to Pricing of Our Products
Insurance coverage and reimbursement of cell and genetic therapies is uncertain
U.S. health-care-law and ACA reforms affecting profitable commercialization of marketed products.
- DroppedRisks Related to Development and Clinical Testing of Our Products and Product Candidates
Our product candidates remain subject to clinical testing and regulatory approval, and our future success is dependent on our ability to successfully develop additional product candidates for both CF and non-CF indications
Challenges commercializing outside the U.S. and obtaining adequate foreign reimbursement.
- DroppedRisks Related to Development and Clinical Testing of Our Products and Product Candidates
If we are unable to obtain or are delayed in obtaining regulatory approval, we may incur additional costs, experience delays, or be unable to commercialize our product candidates
Uncertain insurance coverage and reimbursement for future cell and genetic therapies.
- DroppedRisks Related to Development and Clinical Testing of Our Products and Product Candidates
If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the product candidate could increase and the competitive position of the product candidate could be adversely affected
Clinical testing and regulatory approval requirements for CF and non-CF product candidates.
- DroppedRisks Related to Development and Clinical Testing of Our Products and Product Candidates
Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval
- DroppedRisks Related to Development and Clinical Testing of Our Products and Product Candidates
Enrollment for clinical trials for our cell and gene therapies may face additional and unique challenges and adverse developments associated with these clinical trials could result in action by regulatory bodies, including revised requirements for approval
- DroppedRisks Related to Government Regulation
We are subject to health care fraud and abuse laws, such as the FCA and the AKS, and other similar laws and regulations both in the U.S. and in non-U.S. markets
- DroppedRisks Related to Government Regulation
If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our product candidates
- DroppedRisks Related to Government Regulation
The regulatory approval process for our cell or genetic therapies involves additional consultations with regulatory agencies, costs, and potentially longer timelines as compared to those for small molecules
- DroppedRisks Related to Government Regulation
We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation
- DroppedRisks Related to Government Regulation
If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
- DroppedRisks Related to Supply, Manufacturing and Reliance on Third Parties
We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements
- DroppedRisks Related to Business Development Activities
We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and product candidates
- DroppedRisks Related to Business Development Activities
Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities
- DroppedRisks Related to Business Development Activities
We may not realize the anticipated benefits of existing or future acquisitions of businesses or technologies, and the integration following any such acquisition may disrupt our business and management
- DroppedRisks Related to Intellectual Property
If our patents do not protect our products or our products infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products, substantial damages, or circumvention of our patents by third parties
- DroppedRisks Related to Intellectual Property
Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes that are inherently costly and unpredictable
- DroppedRisks Related to Intellectual Property
We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property
- DroppedRisks Related To Our Operations
A variety of risks associated with operating in foreign countries could materially adversely affect our business
- DroppedRisks Related To Our Operations
A breakdown or breach of our information technology systems could subject us to liability or interrupt the operation of our business
- DroppedRisks Related To Our Operations
We rely on third parties to carry out our operations. Failure to maintain our third-party relationships or challenges at or with these third parties could materially harm our business
- DroppedRisks Related To Our Operations
If our facilities were to experience a catastrophic loss, our operations would be seriously harmed
- DroppedRisks Related to Financial Results and Holding Our Common Stock
Our effective tax rate fluctuates, and changes in tax laws, regulations and treaties, unfavorable resolution to the tax positions we have taken or exposure to additional income tax liabilities could have a material impact on our future taxable income
- DroppedRisks Related to Financial Results and Holding Our Common Stock
Our quarterly operating results are subject to significant fluctuation
- DroppedRisks Related to Financial Results and Holding Our Common Stock
We expect that results from our clinical development activities and the clinical development activities of our competitors will continue to be released periodically, and may result in significant volatility in the price of our common stock
- DroppedGeneral Risk Factors
Issuances of additional shares of our common stock could cause the price of our common stock to decline
- DroppedGeneral Risk Factors
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Reworded
- 100% rewrittenGeneral Risk Factors
The use of social media platforms presents risks and challenges
The risk now adds employee social-media noncompliance, confidential or personal-information disclosure, intellectual-property loss, misinformation, impersonation, reputational damage, and regulatory liability.
Was: The use of social media platforms and artificial intelligence tools presents risks and challenges
- 98% rewrittenRegulatory, Intellectual Property and Other Legal Risks
Our business has a substantial risk of product liability claims and other litigation liability
The discussion narrows from broad litigation exposure to product-liability claims, safety alerts, recalls, reputation, and potentially inadequate insurance coverage.
- 95% rewrittenRisks Related to Our Operations
We may face manufacturing, supply, and distribution delays, difficulties, and disruptions, among other challenges, including at our third-party providers
The risk now specifically lists raw-material and labor shortages, inspections, facility delays, customs, cGMP compliance, global disruptions, and supplier failures.
Was: We may face manufacturing, supply, and distribution difficulties, among other challenges, delays, or interruptions, including at our third-party providers
- 95% rewrittenRisks Related to Our Operations
If we fail to scale our operations to accommodate growth, our business may suffer
The updated risk adds technology and automation, stronger compliance and legal resources, resource prioritization, and foreign-country operating risks.
- 94% rewrittenRisks Related to Our Business and Products
If we are unable to successfully develop and commercialize medicines for acute and neuropathic pain, our business could be materially harmed
The focus shifts from JOURNAVX commercialization generally to lower-cost alternatives, launch execution, follow-on indications, and NaV1.8 and NaV1.7 programs.
Was: If we are unable to successfully develop, obtain approval and commercialize treatments for acute and neuropathic pain, our business could be materially harmed
- 92% rewrittenGeneral Risk Factors
Our stock price is volatile
The stated 2025 trading range is $362.50–$519.68 versus $377.85–$519.88 in 2024, with greater emphasis on clinical updates and financial fluctuations.
Was: Our stock price may fluctuate
- 90% rewrittenGeneral Risk Factors
If we fail to attract and retain skilled employees, our business could be materially harmed
The risk adds intensified competition for cell and genetic therapy talent and warns equity compensation may weaken if Vertex’s stock price declines.
- 86% rewrittenGeneral Risk Factors
Provisions of our articles of organization, by-laws and Massachusetts state laws may frustrate any attempt to remove or replace members of our current Board of Directors and may discourage certain types of business combinations involving us
The updated risk adds Massachusetts restrictions on business combinations and voting by shareholders acquiring at least 20% voting power.
Was: We have adopted provisions in our articles of organization and by-laws and are subject to Massachusetts corporate laws that may frustrate any attempt to remove or replace members of our board or to effectuate certain types of business combinations involving us
- 85% rewrittenRisks Related to Commercialization
If we discover safety or efficacy issues with any of our products, commercialization efforts for the product could be negatively affected, the approved product could lose its approval, and our business could be materially harmed
Was: If we discover safety issues with any of our products or if we fail to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for the product could be negatively affected, the approved product could lose its approval, and our business could be materially harmed
- 55% rewrittenStrategic and Financial Risks
Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreements impose restrictions on our business
Was: Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreements impose restrictions on our business, reducing our operational flexibility and creating default risks
- 34% rewrittenStrategic and Financial Risks
There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices
All 35 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Business and Products
- 01Our success depends on our ability to develop and commercialize additional medicinesNew
- 02Our business is substantially dependent on the success of our CF medicinesNew
- 03If we are unable to successfully develop and commercialize medicines for acute and neuropathic pain, our business could be materially harmed94% rewritten
- 04We may not be able to increase or maintain CASGEVY product revenuesNew
Risks Related to Commercialization
- 05We are subject to pricing and reimbursement pressures that could have a material adverse effect on our business, revenues, and results of operationsNew
- 06In most markets outside of the U.S., the pricing and reimbursement medicines is subject to governmental control and governments are making greater efforts to reduce drug prices and limit drug spending. The reimbursement process in ex-U.SNew
- 07Competing products and technological advances from our competitors may negatively affect our business and market positionNew
- 08If we discover safety or efficacy issues with any of our products, commercialization efforts for the product could be negatively affected, the approved product could lose its approval, and our business could be materially harmed85% rewritten
Risks Related to Product Development
- 09The data from our product development activities may not support advancement or regulatory approval of our product candidates, or label expansions for our marketed products, or provide sufficient data to support the successful commercialization of our approved productsNew
- 10If we fail to successfully conduct our clinical activities, our clinical trials or future regulatory approvals may be delayed or deniedNew
Regulatory, Intellectual Property and Other Legal Risks
- 11The extensive regulatory framework governing the health care industry could adversely affect our ability to obtain approval and market our medicines and failure to comply with these regulations could result in fines, penalties or other non-monetary remediesNew
- 12Commercialization of our products requires that we operate in compliance with applicable health care laws, including laws regulating promotional activities, prohibiting fraud and abuse and requiring reporting of government pricing informationNew
- 13If we are unable to obtain, maintain and enforce our intellectual property rights, our business could be harmedNew
- 14If we are not able to operate without infringing upon intellectual property rights of third parties, our business could be harmedNew
- 15Our business has a substantial risk of product liability claims and other litigation liability98% rewritten
- 16We are subject to a variety of evolving and developing data privacy and security laws and regulations in various jurisdictions related to the collection, storage, use, sharing, and security of personal data, including health informationNew
Risks Related to Our Operations
- 17We may face manufacturing, supply, and distribution delays, difficulties, and disruptions, among other challenges, including at our third-party providers95% rewritten
- 18If we are unable to maintain and expand our supply chain and manufacturing capabilities, our ability to develop our product candidates and manufacture our products would be harmedNew
- 19Reliance on third-party relationships could adversely affect our businessNew
- 20If we fail to scale our operations to accommodate growth, our business may suffer95% rewritten
- 21Our global operations subject us to risks that could adversely affect our business and revenue. In addition to the ex-U.SNew
- 22If any of the above risks were to occur, our revenues, results of operations, financial condition or business could be materially harmedNew
- 23A breakdown or breach of our information technology systems, or unauthorized access to confidential information could adversely affect our businessNew
- 24Cyber-attacks and incidents are increasing in their frequency, sophistication, and intensity, and are difficult to detectNew
- 25Our operations may be disrupted by the occurrence of a natural disaster, catastrophic event, or by other serious accidents occurring at our facilitiesNew
Strategic and Financial Risks
- 26Our business development strategy, including strategic transactions and collaborations, may not be successful, and there may be delays or failures in realizing the anticipated benefits of these activitiesNew
- 27In addition, future strategic transactions could result in potentially dilutive issuances of equity securities or the incurrence of debtNew
- 28Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate globallyNew
- 29Changes in foreign currency rates, interest rate risks, the value of our investment portfolio, and inflation affect our results of operations and financial conditionNew
- 30Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreements impose restrictions on our business55% rewritten
- 31There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices34% rewritten
General Risk Factors
- 32Our stock price is volatile92% rewritten
- 33If we fail to attract and retain skilled employees, our business could be materially harmed90% rewritten
- 34The use of social media platforms presents risks and challenges100% rewritten
- 35Provisions of our articles of organization, by-laws and Massachusetts state laws may frustrate any attempt to remove or replace members of our current Board of Directors and may discourage certain types of business combinations involving us86% rewritten
Other Vertex Pharmaceuticals 10-Ks
- FY2024 10-K risk factors50 risks
CF medicines generate substantially all recent net product revenue, making continued CF sales the company’s dominant financial dependency.
Filed Feb 13, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.